

What is the best anti-scarring treatment for combined cataract and drainage surgery in routine operations for combined glaucoma and cataract in Tanzania?

Submission date 24/09/2009	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 30/11/2009	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 09/09/2016	Condition category Eye Diseases	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Mr Ian Murdoch

Contact details
Epidemiology and International Eye Health
Department of Genetics
Institute of Ophthalmology
Bath Street
London
United Kingdom
EC1V 9EL
-
i.murdoch@ucl.ac.uk

Additional identifiers

Study information

Scientific Title

Is beta-radiation better than 5-fluorouracil as an adjunct for trabeculectomy when combined with cataract surgery? A single centre randomised controlled trial

Study objectives

Beta radiation offers improved pressure control with a retained safety profile when used as an adjunct in combined trabeculectomy and cataract surgery.

Ethics approval required

Old ethics approval format

Ethics approval(s)

National Institute for Medical Research and Ministry of Health and Social Welfare, Dar es Salaam (Tanzania) provided clearance certificates for conducting Medical Research in Tanzania, 25/07/2008 and 13/08/2008, ref: NIMR/HQ/R.8a/Vol.IX/717 and NIMR/HQ/R.8a/Vol.IX/723

Study design

Single-centre randomised controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Open angle glaucoma

Interventions

Patients are randomised to either 5-fluorouracil or beta-radiation as follows:

1. 5-fluorouracil is applied subconjunctivally for a period of 3 minutes at a concentration of 50 mg/ml prior to undertaking the drainage flap
2. Beta-radiation is applied with a Strontium-90 containing delivery device to the closed conjunctival surface at the conclusion of surgery. Using the decay chart for the probe the correct time interval is used to deliver 1000 cGy of Beta irradiation (approximately 8 minutes). The main outcome is at one year post-operatively.

Intervention Type

Drug

Phase

Phase III

Drug/device/biological/vaccine name(s)

Beta-radiation, 5-fluorouracil

Primary outcome(s)

Intraocular pressure at 12 months post-operatively. Surgical success at twelve months is defined as a maximum intraocular pressure less than 16 mmHg as measured using Goldmann tonometry on no ocular hypotensive therapy.

Key secondary outcome(s)

1. Visual function, assessed within or at the first year after surgery
2. Reintervention, assessed within or at the first year after surgery
3. Reintervention acceptance, assessed within or at the first year after surgery
4. Surgical complications, measured during surgery and within two weeks of surgery

Completion date

01/05/2014

Eligibility

Key inclusion criteria

1. Consent to inclusion and participation in trial
2. Characteristic glaucomatous changes in the optic disc. The presence of a focal or diffuse area of optic disc rim loss, so that the neuroretinal rim tissue in any quadrant is less than 5% of the disc diameter in that meridian. Extensive loss of neuroretinal rim tissue with marked optic disc cupping giving a cup disc ratio greater than 0.8.
3. A measured intraocular pressure greater than or equal to 21 mmHg on at least one visit before the time of listing for surgery as measured by Goldmann applanation tonometry
4. An open angle on gonioscopy
5. Visually significant cataract
6. Aged greater than 20 years, either sex

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

1. Unwillingness to participate in the study
2. Anterior segment neovascularisation
3. Past trauma to the eye or ocular adnexae
4. Retinal or optic nerve neovascularisation
5. Aphakia or pseudophakia
6. Previous ocular surgery
7. Uveitis
8. Inability/unwillingness to give informed consent
9. Unwillingness to accept randomisation
10. Patient less than 20 years of age
11. Pregnancy or female of childbearing age who may be pregnant at time of treatment (last menstrual period [LMP])
12. No clinically significant cataract
13. Chronic use of topical or systemic steroids

Date of first enrolment

01/05/2009

Date of final enrolment

01/05/2014

Locations

Countries of recruitment

United Kingdom

England

Tanzania

Study participating centre

Institute of Ophthalmology

London

United Kingdom

EC1V 9EL

Sponsor information

Organisation

University College London (UCL) (UK)

ROR

<https://ror.org/02jx3x895>

Funder(s)

Funder type

Charity

Funder Name

Fight for Sight (UK) (ref: DFFM/UCL)

Alternative Name(s)

Fight for Sight, Inc., National Council to Combat Blindness, Fight for Sight (U.S.), FFS

Funding Body Type

Government organisation

Funding Body Subtype

Trusts, charities, foundations (both public and private)

Location

United States of America

Funder Name

International Glaucoma Association (UK) (ref: DEHC/UCL)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	08/09/2016		Yes	No